^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-1501
i
Other names: SHR-1501
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
IL-15R agonist
Related drugs:
over1year
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CD8 (cluster of differentiation 8)
|
SHR-1501 • adebrelimab (SHR-1316)
almost2years
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (clinicaltrials.gov)
P1, N=14, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting | N=104 --> 14 | Trial completion date: Jun 2023 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Sep 2022
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
CD8 (cluster of differentiation 8)
|
SHR-1501 • adebrelimab (SHR-1316)
Share via
